Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07407933 · ClinicalTrials.gov registry record · Phase 1
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by MediLink Therapeutics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT07407933 is a Phase 1 study that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 118 participants.
The verdict
NCT07407933, a Phase 1 study, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.
Interventions
- DRUG Atezolizumab
- DRUG YL201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07407933
The ClinicalTrials.gov registry entry for NCT07407933 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediLink Therapeutics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT07407933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07407933 about?
NCT07407933 is a clinical study titled "A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors". This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of ate...
What is the current status of trial NCT07407933?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2026-03-31. Estimated completion is 2029-02.
What interventions are being tested in trial NCT07407933?
The interventions under investigation include: Atezolizumab (DRUG), YL201 (DRUG).
Who is sponsoring clinical trial NCT07407933?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.